Acute Myeloid Leukemia Coverage From Every Angle
Advertisement
Advertisement

Ehab L. Atallah, MD, on AML and COVID-19: Expert Guidance on Administering Venetoclax and TKIs

Posted: Tuesday, May 12, 2020

Ehab L. Atallah, MD, of the Medical College of Wisconsin, talks about whether, during the COVID-19 pandemic, patients with acute myeloid leukemia should continue targeted treatments such as venetoclax or tyrosine kinase inhibitors, which may cause adverse effects to the lungs.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.